Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06487624 · ClinicalTrials.gov registry record · Phase 1
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
A Phase 1 study of Advanced Solid Tumor and Refractory Hodgkin Lymphoma, sponsored by FBD Biologics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 6
- Study locations
NCT06487624: Recruiting Phase 1 study of Advanced Solid Tumor and Refractory Hodgkin Lymphoma, sponsored by FBD Biologics Limited.
NCT06487624 is a Phase 1 study of Advanced Solid Tumor and Refractory Hodgkin Lymphoma that is actively recruiting participants, run by FBD Biologics Limited. The registered enrollment target is 50 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (74% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06487624, a Phase 1 study of Advanced Solid Tumor and Refractory Hodgkin Lymphoma, is actively recruiting participants, sponsored by FBD Biologics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Primary Outcome
To evaluate the safety and tolerability of HCB301.
Conditions Studied
Interventions
- DRUG HCB301
Study Locations (6)
Other
- The First Affiliated Hospital, Zhejiang University School of Medicine - Hangzhou
- Zhejiang Provincial Cancer Hospital - Hangzhou
- Xuzhou Central Hospital - Xuzhou
- Yantai Yuhuangding Hospital - Yantai
- Southern Medical University Zhujiang Hospital - Zhujiang
South Carolina
- Prisma Health-Upstate - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-04-02 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
What NCT06487624 shows while recruiting
NCT06487624 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which HCB301 is the first listed.
NCT06487624 lists 6 locations in 2 states (Other, South Carolina).
Frequently Asked Questions
What is clinical trial NCT06487624 about?
NCT06487624 is a clinical study titled "An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors". The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
What is the current status of trial NCT06487624?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-04-02. Estimated completion is 2027-05-31.
What conditions does trial NCT06487624 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Refractory Hodgkin Lymphoma.
What interventions are being tested in trial NCT06487624?
The interventions under investigation include: HCB301 (DRUG).
Who is sponsoring clinical trial NCT06487624?
This trial is sponsored by FBD Biologics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06487624 being conducted?
This trial has 6 study locations across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06487624's enrollment target sits among peer trials
50 159th of 189 higher than 29 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI